These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
385 related articles for article (PubMed ID: 32904605)
21. Comprehensive analysis of TPX2-related ceRNA network as prognostic biomarkers in lung adenocarcinoma. Huo C; Zhang MY; Li R; Zhou XJ; Liu TT; Li JP; Liu X; Qu YQ Int J Med Sci; 2020; 17(16):2427-2439. PubMed ID: 33029085 [No Abstract] [Full Text] [Related]
22. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma. Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465 [TBL] [Abstract][Full Text] [Related]
23. LINC00467 Is Upregulated by DNA Copy Number Amplification and Hypomethylation and Shows ceRNA Potential in Lung Adenocarcinoma. Wang W; Bo H; Liang Y; Li G Front Endocrinol (Lausanne); 2021; 12():802463. PubMed ID: 35095769 [TBL] [Abstract][Full Text] [Related]
24. Comprehensive analysis of prognostic biomarkers in lung adenocarcinoma based on aberrant lncRNA-miRNA-mRNA networks and Cox regression models. Yao Y; Zhang T; Qi L; Liu R; Liu G; Wang J; Song Q; Sun C Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31950990 [TBL] [Abstract][Full Text] [Related]
25. Development and validation of a robust immune-related prognostic signature in early-stage lung adenocarcinoma. Wu P; Zheng Y; Wang Y; Wang Y; Liang N J Transl Med; 2020 Oct; 18(1):380. PubMed ID: 33028329 [TBL] [Abstract][Full Text] [Related]
26. Overexpression of CENPF is associated with progression and poor prognosis of lung adenocarcinoma. Li MX; Zhang MY; Dong HH; Li AJ; Teng HF; Liu AL; Xu N; Qu YQ Int J Med Sci; 2021; 18(2):494-504. PubMed ID: 33390818 [No Abstract] [Full Text] [Related]
27. Downregulation of AHNAK2 inhibits cell cycle of lung adenocarcinoma cells by interacting with RUVBL1. Li X; Li H; Shao MM; Miao J; Fu Y; Hu B Thorac Cancer; 2023 Aug; 14(22):2093-2104. PubMed ID: 37349884 [TBL] [Abstract][Full Text] [Related]
28. Synaptotagmin 12 (SYT12) Gene Expression Promotes Cell Proliferation and Progression of Lung Adenocarcinoma and Involves the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) Pathway. Liu K; Luo J; Shao C; Ren Z; Sun S; Zhu Y; Zhou H; Jiang Z; Li X; Gu W; Xu Y; Qiang Y; Ren B; Xu L; Wu H; Shen Y Med Sci Monit; 2020 Feb; 26():e920351. PubMed ID: 32108133 [TBL] [Abstract][Full Text] [Related]
29. Elevated expression of Twinfilin-1 is correlated with inferior prognosis of lung adenocarcinoma. Kaishang Z; Xue P; Shaozhong Z; Yingying F; Yan Z; Chanjun S; Zhenzhen L; Xiangnan L Life Sci; 2018 Dec; 215():159-169. PubMed ID: 30391462 [TBL] [Abstract][Full Text] [Related]
30. Significance of novel PANoptosis genes to predict prognosis and therapy effect in the lung adenocarcinoma. Miao Z; Yu W Sci Rep; 2024 Sep; 14(1):20934. PubMed ID: 39251701 [TBL] [Abstract][Full Text] [Related]
31. Characterization of an endoplasmic reticulum stress-associated lncRNA prognostic signature and the tumor-suppressive role of RP11-295G20.2 knockdown in lung adenocarcinoma. Yu L; Zhou S; Hong W; Lin N; Wang Q; Liang P Sci Rep; 2024 May; 14(1):12283. PubMed ID: 38811828 [TBL] [Abstract][Full Text] [Related]
32. MicroRNA-147b promotes lung adenocarcinoma cell aggressiveness through negatively regulating microfibril-associated glycoprotein 4 (MFAP4) and affects prognosis of lung adenocarcinoma patients. Feng YY; Liu CH; Xue Y; Chen YY; Wang YL; Wu XZ Gene; 2020 Mar; 730():144316. PubMed ID: 31884109 [TBL] [Abstract][Full Text] [Related]
33. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma. Xu XL; Gong Y; Zhao DP Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913 [TBL] [Abstract][Full Text] [Related]
34. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related]
35. Significance of Lin H; Wang J; Shi Q; Wu M PeerJ; 2024; 12():e17338. PubMed ID: 38708353 [TBL] [Abstract][Full Text] [Related]
36. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related]
37. High Expression of Deng H; Huang Y; Wang L; Chen M Biomed Res Int; 2020; 2020():2071593. PubMed ID: 33134373 [TBL] [Abstract][Full Text] [Related]
38. Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma. Pan Y; Jin X; Xu H; Hong J; Li F; Luo T; Zeng J Sci Rep; 2024 Jun; 14(1):13113. PubMed ID: 38849442 [TBL] [Abstract][Full Text] [Related]
39. Identification of a novel prognosis-associated ceRNA network in lung adenocarcinoma via bioinformatics analysis. Li Y; Yu X; Zhang Y; Wang X; Zhao L; Liu D; Zhao G; Gao X; Fu J; Zang A; Jia Y Biomed Eng Online; 2021 Nov; 20(1):117. PubMed ID: 34819106 [TBL] [Abstract][Full Text] [Related]
40. Identification of a necroptosis-related gene signature for making clinical predictions of the survival of patients with lung adenocarcinoma. Zhou X; Zhao M; Fan Y; Xu Y PeerJ; 2024; 12():e16616. PubMed ID: 38213773 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]